Full text is available at the source.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Jun 13, 2019Lancet (London, England)
Comparing oral semaglutide, injected liraglutide, and placebo in type 2 diabetes treatment
AI simplified
Abstract
Oral semaglutide resulted in a mean change in glycated haemoglobin (HbA) of -1.2% at week 26.
- Oral semaglutide was non-inferior to subcutaneous liraglutide in reducing HbA levels.
- Oral semaglutide was superior to placebo in lowering HbA levels by -1.1%.
- Patients taking oral semaglutide experienced significantly greater weight loss of -4.4 kg compared to -3.1 kg with liraglutide and -0.5 kg with placebo.
- Adverse events occurred more frequently with oral semaglutide (80%) and liraglutide (74%) compared to placebo (67%).
- The safety and tolerability of oral semaglutide were similar to those of subcutaneous liraglutide.
AI simplified
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for type 2 diabetes, lowering glycated haemoglobin (HbA) and weight, but are currently only approved for use as subcutaneous injections. Oral semaglutide, a novel GLP-1 agonist, was compared with subcutaneous liraglutide and placebo in patients with type 2 diabetes. 1c
METHODS: In this randomised, double-blind, double-dummy, phase 3a trial, we recruited patients with type 2 diabetes from 100 sites in 12 countries. Eligible patients were aged 18 years or older, with HbAof 7·0-9·5% (53-80·3 mmol/mol), on a stable dose of metformin (≥1500 mg or maximum tolerated) with or without a sodium-glucose co-transporter-2 inhibitor. Participants were randomly assigned (2:2:1) with an interactive web-response system and stratified by background glucose-lowering medication and country of origin, to once-daily oral semaglutide (dose escalated to 14 mg), once-daily subcutaneous liraglutide (dose escalated to 1·8 mg), or placebo for 52 weeks. Two estimands were defined: treatment policy (regardless of study drug discontinuation or rescue medication) and trial product (assumed all participants were on study drug without rescue medication) in all participants who were randomly assigned. The treatment policy estimand was the primary estimand. The primary endpoint was change from baseline to week 26 in HbA(oral semaglutide superiority vs placebo and non-inferiority [margin: 0·4%] and superiority vs subcutaneous liraglutide) and the confirmatory secondary endpoint was change from baseline to week 26 in bodyweight (oral semaglutide superiority vs placebo and liraglutide). Safety was assessed in all participants who received at least one dose of study drug. This trial is registered on Clinicaltrials.gov, number NCT02863419, and the European Clinical Trials registry, number EudraCT 2015-005210-30. 1c1c
FINDINGS: Between Aug 10, 2016, and Feb 7, 2017, 950 patients were screened, of whom 711 were eligible and randomly assigned to oral semaglutide (n=285), subcutaneous liraglutide (n=284), or placebo (n=142). 341 (48%) of 711 participants were female and the mean age was 56 years (SD 10). All participants were given at least one dose of study drug, and 277 (97%) participants in the oral semaglutide group, 274 (96%) in the liraglutide group, and 134 (94%) in the placebo group completed the 52-week trial period. Mean change from baseline in HbAat week 26 was -1·2% (SE 0·1) with oral semaglutide, -1·1% (SE 0·1) with subcutaneous liraglutide, and -0·2% (SE 0·1) with placebo. Oral semaglutide was non-inferior to subcutaneous liraglutide in decreasing HbA(estimated treatment difference [ETD] -0·1%, 95% CI -0·3 to 0·0; p<0·0001) and superior to placebo (ETD -1·1%, -1·2 to -0·9; p<0·0001) by use of the treatment policy estimand. By use of the trial product estimand, oral semaglutide had significantly greater decreases in HbAthan both subcutaneous liraglutide (ETD -0·2%, 95% CI -0·3 to -0·1; p=0·0056) and placebo (ETD -1·2%, -1·4 to -1·0; p<0·0001) at week 26. Oral semaglutide resulted in superior weight loss (-4·4 kg [SE 0·2]) compared with liraglutide (-3·1 kg [SE 0·2]; ETD -1·2 kg, 95% CI -1·9 to -0·6; p=0·0003) and placebo (-0·5 kg [SE 0·3]; ETD -3·8 kg, -4·7 to -3·0; p<0·0001) at week 26 (treatment policy). By use of the trial product estimand, weight loss at week 26 was significantly greater with oral semaglutide than with subcutaneous liraglutide (-1·5 kg, 95% CI -2·2 to -0·9; p<0·0001) and placebo (ETD -4·0 kg, -4·8 to -3·2; p<0·0001). Adverse events were more frequent with oral semaglutide (n=229 [80%]) and subcutaneous liraglutide (n=211 [74%]) than with placebo (n=95 [67%]). 1c1c1c
INTERPRETATION: Oral semaglutide was non-inferior to subcutaneous liraglutide and superior to placebo in decreasing HbA, and superior in decreasing bodyweight compared with both liraglutide and placebo at week 26. Safety and tolerability of oral semaglutide were similar to subcutaneous liraglutide. Use of oral semaglutide could potentially lead to earlier initiation of GLP-1 receptor agonist therapy in the diabetes treatment continuum of care. 1c
FUNDING: Novo Nordisk A/S.
Related papers
Jun '19
Effectiveness and safety of oral semaglutide in type 2 diabetes patients with moderate kidney problems
top 1% journal
cited by 274 papers
randomized controlled trial
Jun '19
Effectiveness and safety of adjustable oral semaglutide compared to sitagliptin in type 2 diabetes
top 1% journal
cited by 235 papers
randomized controlled trial
Apr '17
Weekly semaglutide compared to daily sitagliptin added to diabetes pills in type 2 diabetes over 56 weeks: a safety and effectiveness trial
top 1% journal
cited by 420 papers
randomized controlled trial
Jul '21
Effectiveness and safety of once-weekly 2.0 mg versus 1.0 mg semaglutide in people with type 2 diabetes
top 1% journal
cited by 152 papers
randomized controlled trial
Sep '19
Weekly semaglutide versus daily canagliflozin added to metformin for type 2 diabetes: effectiveness and safety in a controlled trial
top 1% journal
cited by 244 papers
randomized controlled trial
Mar '17
Effectiveness and safety of weekly semaglutide compared to daily insulin glargine added to metformin in people with type 2 diabetes who have not used insulin
top 1% journal
cited by 393 papers
randomized controlled trial
Jul '24
Effectiveness and safety of oral semaglutide compared to sitagliptin in mostly Chinese adults with type 2 diabetes not controlled by metformin
top 2% journal
cited by 18 papers
randomized controlled trial
Jul '24
Effectiveness and safety of oral semaglutide alone compared to placebo in mostly Chinese adults with type 2 diabetes
top 2% journal
cited by 22 papers
randomized controlled trial
Apr '20
Effects, safety, and best dose of oral semaglutide alone in Japanese people with type 2 diabetes over 52 weeks
top 1% journal
cited by 188 papers
randomized controlled trial
Jan '17
Effectiveness and safety of once-weekly semaglutide alone compared to placebo in people with type 2 diabetes
top 1% journal
cited by 621 papers
randomized controlled trial